Hepatocellular carcinoma

Hepatocellular carcinoma
Name	Hepatocellular carcinoma
Field	Oncology, Hepatology
Symptoms	Jaundice, abdominal pain, weight loss
Complications	Portal hypertension, hepatic failure, metastasis
Onset	Adult
Causes	Chronic liver disease, cirrhosis
Risks	Hepatitis B, Hepatitis C, aflatoxin
Diagnosis	Imaging, biopsy, alpha-fetoprotein
Treatment	Resection, transplantation, locoregional therapy, systemic therapy
Prognosis	Variable

Hepatocellular carcinoma is the most common primary malignant tumor of the liver, arising in the setting of chronic liver disease and cirrhosis and causing substantial global morbidity and mortality. It intersects with public health initiatives, infectious disease control, surgical oncology, and transplantation programs and influences policy discussions involving agencies such as the World Health Organization, Centers for Disease Control and Prevention, National Institutes of Health, and European Medicines Agency. Management involves multidisciplinary teams including hepatologists, oncologists, transplant surgeons, and interventional radiologists from institutions such as Massachusetts General Hospital, Mayo Clinic, MD Anderson Cancer Center, and Royal Free Hospital.

Overview

Hepatocellular carcinoma occurs when hepatocytes acquire malignant transformation often after decades of chronic injury, linking pathways studied at institutions like Cold Spring Harbor Laboratory, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, and Johns Hopkins Hospital. The disease course and treatment paradigms have been shaped by landmark trials from cooperative groups such as the European Organisation for Research and Treatment of Cancer, American Society of Clinical Oncology, Intercontinental Hepato-Pancreato-Biliary Association, and Asia-Pacific Hepatology networks. Diagnostic algorithms integrate imaging criteria established by the American College of Radiology, Liver Imaging Reporting and Data System, and guidelines from the American Association for the Study of Liver Diseases.

Epidemiology and Risk Factors

Incidence and mortality patterns show geographic heterogeneity with high burden in East Asia, sub-Saharan Africa, and parts of South America, reflecting interactions among hepatitis viruses, aflatoxin exposure, alcohol use, and metabolic conditions monitored by agencies like the World Bank and United Nations. Major risk factors include chronic infection with hepatitis B virus and hepatitis C virus, exposure to aflatoxins associated with agricultural practices in regions studied by the Food and Agriculture Organization and World Food Programme, alcohol-related liver disease tracked by the Global Burden of Disease collaborators, and nonalcoholic steatohepatitis driven by obesity trends reported by the Centers for Disease Control and Prevention, National Health Service, and Australian Institute of Health and Welfare. Additional contributors such as hemochromatosis, Wilson disease, and alpha-1 antitrypsin deficiency are managed in specialty centers including Great Ormond Street Hospital and Cleveland Clinic.

Pathophysiology and Genetics

Carcinogenesis involves chronic inflammation, fibrosis, and cirrhosis mediated by cytokine networks characterized in laboratories at Institut Pasteur, Max Planck Institute, and Salk Institute; molecular alterations include telomerase activation, WNT/β-catenin pathway mutations, TP53 mutations often linked to aflatoxin, and chromatin remodeling defects involving ARID1A and ARID2 identified in genomic studies from The Cancer Genome Atlas, International Cancer Genome Consortium, and Broad Institute. Clonal evolution and tumor heterogeneity have been illuminated by single-cell and spatial transcriptomics projects at the European Molecular Biology Laboratory, Wellcome Sanger Institute, and Howard Hughes Medical Institute, while hepatitis B virus integration and hepatitis C virus–related oncogenic signaling remain active research areas in virology centers such as Institut Pasteur and Centers for Disease Control and Prevention.

Clinical Presentation and Diagnosis

Patients typically present with right upper quadrant pain, weight loss, and decompensated liver disease; clinical assessment leverages hepatology expertise from Royal Free Hospital, King's College Hospital, and St Thomas' Hospital. Diagnostic workup combines multiphase contrast-enhanced magnetic resonance imaging and computed tomography protocols standardized by the American College of Radiology and European Society of Radiology, serum biomarkers including alpha-fetoprotein assays validated in laboratories at Mayo Clinic and Karolinska Institute, and percutaneous biopsy when imaging is equivocal with pathological evaluation guided by College of American Pathologists and Royal College of Pathologists criteria. Staging evaluation often involves positron emission tomography resources at academic centers like Memorial Sloan Kettering Cancer Center and technical input from interventional radiology divisions at Massachusetts General Hospital.

Staging and Prognostic Factors

Prognosis is determined by tumor burden, vascular invasion, extrahepatic spread, and underlying liver function assessed by Child–Pugh score and Model for End-Stage Liver Disease calculated in transplant listings managed by United Network for Organ Sharing, Eurotransplant, and NHS Blood and Transplant. Staging systems widely used include the Barcelona Clinic Liver Cancer system developed by clinicians in Barcelona, AJCC/UICC TNM staging codified by the American Joint Committee on Cancer and International Union Against Cancer, and the Milan criteria informing transplantation candidacy from research at the University of Milan and University of California. Biomarkers, performance status indices, and response criteria such as RECIST and modified RECIST guide prognosis estimation in trials from Cooperative Oncology Groups.

Treatment and Management

Curative options include surgical resection and liver transplantation with candidate selection influenced by outcomes reported from centers like the University of Toronto, King's College Hospital, and University of California San Francisco. Locoregional therapies include radiofrequency ablation, microwave ablation, transarterial chemoembolization, and selective internal radiation therapy performed at interventional suites in MD Anderson Cancer Center and Institut Gustave Roussy. Systemic therapy has evolved with multikinase inhibitors such as sorafenib and lenvatinib; immune checkpoint inhibitors and combination regimens emerged from trials led by pharmaceutical companies and cooperative groups including Roche, Bristol Myers Squibb, Merck, and Pfizer, with regulatory review by the FDA and EMA. Supportive care integrates palliative services at hospice organizations and symptom management protocols from WHO palliative care guidance.

Prevention and Screening

Primary prevention emphasizes hepatitis B vaccination programs promoted by WHO and GAVI Alliance, safe blood transfusion practices overseen by Red Cross and national blood services, aflatoxin mitigation efforts by Food and Agriculture Organization and national agriculture ministries, and obesity control initiatives by CDC and NHS. Screening strategies for high-risk populations use ultrasound and alpha-fetoprotein surveillance as recommended in guidelines from the American Association for the Study of Liver Diseases, European Association for the Study of the Liver, and Asian Pacific Association for the Study of the Liver; population-level policy implementations have been piloted in Taiwan, Japan, and South Korea with outcomes reported by national health ministries and public health agencies.

Category:Liver neoplasia